Print

CDK inhibitors may increase survival for ER-positive metastatic breast cancer patients

https://www.facingourrisk.org/XRAY/CDK-inhibitors-for-metastatic-breast-cancer
Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1903765

The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19) 

 

 

Questions To Ask Your Health Care Provider

 

Open Clinical Trials

The following studies look at treatment for people with metastatic ER-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 

 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.